2015 ASCO Journal Club Special Topic: Sarcoma

Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in sarcoma. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.

Articles covered in this quarter’s review include:

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients with resectable High-Grade Osteosarcoma and Good Histologic Response to Pre-operative MAP:  First Results of the EURAMOS-1 Good Response Randomized Controlled Trial; Bielack SS, et al. J Clin Oncol. 2015; 33(20): 2279-2297.

  • Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide; Palassini E, et al. J Clin Oncol. 2015: 33(31); 3628-3634.

  • Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma; Ahmed N, et al. J Clin Oncol. 2015: 33(15); 1688-1696.

Learning Objectives

  • Discuss standard osteosarcoma treatment and prognostic features and analyze additional therapy to the current standard of care for good histologic response osteosarcoma post-operatively
  • Explain standard high-grade soft tissue sarcoma treatment and recognize the feasibility of pre-operative radiation therapy and concomitant chemotherapy in high risk soft tissue sarcoma treatment
  • Review the use of immunotherapy in cancer and evaluate the application of CAR T cell technology to sarcomas
  • Apply knowledge learned to enhance the care delivered to patients with sarcoma

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred. 

Important Notes

  • This course expires on December 2, 2018. Participants must complete all necessary course components by this date to receive credit.